NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Open Access
- 15 May 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 105 (10), 3939-3944
- https://doi.org/10.1182/blood-2004-09-3707
Abstract
The presence of a metaphase cytogenetic abnormality (CA) is the key negative predictor of outcome in patients with multiple myeloma (MM). Gene expresKeywords
This publication has 70 references indexed in Scilit:
- NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast TumorsCancer Research, 2004
- Treatment of multiple myelomaBlood, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Identification of NY‐ESO‐1, MAGE‐1, and MAGE‐3 in head and neck squamous cell carcinomaHead & Neck, 2003
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood, 2003
- Identification of immunodominant regions among promiscuous HLA-DR–restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3Blood, 2003
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplantsBritish Journal of Haematology, 2002
- Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissuesInternational Journal of Cancer, 2001
- Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatmentBone Marrow Transplantation, 1997